Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Different graft-vs-host disease prophylaxis strategy for allogeneic hematopoietic stem cell transplantation in adults with chronic active EBV infection

Min Liu, Qiuxia Yu, Yang Cao, Jia Wei, Yaxian Ma, Zetong Hong, Qing Yin, Yan Feng, ZhaoYang Hong, Tongjuan Li, Jia Gu, Liting Chen, Yicheng Zhang, Miao Zheng

Blood (2025) 146 (Supplement 1): 7758.

https://doi.org/10.1182/blood-2025-7758

Published: 2025

Journal Articles

Survival prediction in relapsed/refractory B-cell lymphoma treated with CAR-T therapy: An AI-optimized cox regression model based on CCL5, scgf-β, and TRAIL

Hu Qian, Zekai Mao, Anqi Zhang, Xiaoying Zhang, Xingcheng Yang, Juan Peng, Jiaqi Guo, Liting Chen, Hui Luo, Li Zhu, Xiaoxi Zhou, Yang Yang, Na Wang, Jue Wang, Yicheng Zhang, Jia Wei

Blood (2025) 146 (Supplement 1): 4115.

https://doi.org/10.1182/blood-2025-4115

Published: 2025

Journal Articles

Higher ability of the bone marrow chimerism rate compared with the sorted t-cell chimerism rate to predict AML relapse

Liting Chen, Tongyuan Liu, Chunfeng Li, Lijun Jiang, Lifang Huang

Blood (2025) 146 (Supplement 1): 7798.

https://doi.org/10.1182/blood-2025-7798

Published: 2025

Journal Articles

Long-term follow-up reveals sustained benefit of dual CD19/CD22 CAR T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma

Juan Peng, Zekai Mao, Yang Cao, Na Wang, Jue Wang, Yang Yang, Jinghuan Xu, Fankai Meng, Liting Chen, Xia Mao, Jiaqi Guo, Xiaoxi Zhou, Yicheng Zhang, Jia Wei

Blood (2025) 146 (Supplement 1): 3712.

https://doi.org/10.1182/blood-2025-3712

Published: 2025

Journal Articles

Characteristics of the spatio-temporal distributions of chimeric antigen receptor T cells based on real-world evidence

Liting Chen, Man Zhang

Blood (2025) 146 (Supplement 1): 7664.

https://doi.org/10.1182/blood-2025-7664

Published: 2025

Journal Articles

Improving CAR-T Cell Function through a Targeted Cytokine Delivery System Utilizing CAR Target-Modified Extracellular Vesicles

Yuanyuan Zhang, Meijuan Huang, Tianjiao Liu, Yuhang Cheng, Dengju Li, Yang Cao, Wei Mu, Liting Chen, Li Zhu, Tongjuan Li, Liang Huang, Jia Wei, Lei Zhao, Jue Wang

Blood (2024) 144 (Supplement 1): 3419.

https://doi.org/10.1182/blood-2024-206731

Published: 2024

Journal Articles

Prediction of Organs Toxicity during CAR T-Cell Therapy By Using Cell-Free DNA Markers

Liting Chen, Qiyang Han, Yan Zhang, Guodan Zeng, Yuekun Fang, Man Zhang, Jia Wei, Yicheng Zhang

Blood (2024) 144 (Supplement 1): 4782.

https://doi.org/10.1182/blood-2024-194685

Published: 2024

Journal Articles

3D Live Imaging and Phenotyping of the Subcellular Cytotoxicity in CAR-T Cell Immunotherapy

Liting Chen, Zhaofei Wang, Jie Wang, Jin Jin, Jia Wei, Yicheng Zhang, Peng Fei

Blood (2024) 144 (Supplement 1): 4781.

https://doi.org/10.1182/blood-2024-193597

Published: 2024

Journal Articles

Reflecting In Vivo Spatio-Temporal Distribution Characteristics of CAR-T Cells through Real-World Clinical Samples

Man Zhang, Liting Chen, Caixia Chen, Jia Wei, Yicheng Zhang, Yi Xiao

Blood (2024) 144 (Supplement 1): 7125.

https://doi.org/10.1182/blood-2024-194628

Published: 2024

Journal Articles

Functional Diversification and Dynamics of CAR-T Cells in B-ALL Patients

Blood (2023) 142 (Supplement 1): 4851.

https://doi.org/10.1182/blood-2023-178624

Published: 2023

Journal Articles

Soluble PD-L1 Predicts Poor Outcome and Disease Progression in Patients with De Novo Myelodysplastic Syndromes

Xingcheng Yang, Xiaoying Zhang, Juan Peng, Lifang Huang, Shaolong He, Zhiqiong Wang, Liting Chen, Chunrui Li, Ling Ma, Jia Wei

Blood (2023) 142 (Supplement 1): 6448.

https://doi.org/10.1182/blood-2023-190744

Published: 2023

Journal Articles

MIP3α As an Early Prognostic Predictor for Patients with B-Cell Malignancies Receiving CD19/CD22-Redirected CAR T-Cell Cocktail Therapy

Jin Jin, Jiali Cheng, Na Wang, Liang Huang, Xiaoxi Zhou, Liting Chen, Hui Luo, Tianjiao Liu, Jiao Meng

Blood (2022) 140 (Supplement 1): 10265–10266.

https://doi.org/10.1182/blood-2022-156710

Published: 2022

Journal Articles

Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 7435–7436.

https://doi.org/10.1182/blood-2022-166465

Published: 2022

Journal Articles

A Phase 1/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 547.

https://doi.org/10.1182/blood-2021-152576

Published: 2021

Journal Articles

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

Blood (2021) 137 (21): 2890–2901.

https://doi.org/10.1182/blood.2020008936

Published: 2021

Includes: Supplemental data

Journal Articles

CD19/CD22 CAR-T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory B-Cell Lymphomas

Yang Cao, Yi Xiao, Na Wang, MD PhD, Gaoxiang Wang, MDPhD, Xiaoxi Zhou, MDPhD, Liang Huang, MD, Liting Chen, PhD, Min Xiao, MD PhD, Tongcun Zhang, PhD, Yicheng Zhang, Jianfeng Zhou, MD PhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-140308

Published: 2020

Journal Articles

Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies

Blood (2020) 135 (1): 17–27.

https://doi.org/10.1182/blood.2019000017

Published: 2020

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Chunrui Li, MD PhD, Jue Wang, MD PhD, Di Wang, MD PhD, Guang Hu, Yongkun Yang, Xiaoxi Zhou, MD PhD, Li Meng, MD PhD, Zhenya Hong, MD PhD, Liting Chen, PhD, Xia Mao, MD PhD, Min Xiao, MD PhD, Jianfeng Zhou, MD PhD

Blood (2019) 134 (Supplement_1): 929.

https://doi.org/10.1182/blood-2019-128468

Published: 2019

Journal Articles

Autonomous Ca 2+ Oscillations Reflect Oncogenic Signaling in B-ALL Cells

Kohei Kume, PhD, Liting Chen, PhD, Jaewoong Lee, PhD, Markus Müschen, MD PhD

Blood (2019) 134 (Supplement_1): 1253.

https://doi.org/10.1182/blood-2019-130708

Published: 2019

Journal Articles

Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling

Blood (2019) 134 (Supplement_1): 393.

https://doi.org/10.1182/blood-2019-131270

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Different graft-vs-host disease prophylaxis strategy for allogeneic hematopoietic stem cell transplantation in adults with chronic active EBV infection

Survival prediction in relapsed/refractory B-cell lymphoma treated with CAR-T therapy: An AI-optimized cox regression model based on CCL5, scgf-β, and TRAIL

Higher ability of the bone marrow chimerism rate compared with the sorted t-cell chimerism rate to predict AML relapse

Long-term follow-up reveals sustained benefit of dual CD19/CD22 CAR T-cell therapy alone or combined with autologous stem cell transplantation in TP53-altered relapsed/refractory B-cell non-Hodgkin lymphoma

Characteristics of the spatio-temporal distributions of chimeric antigen receptor T cells based on real-world evidence

Improving CAR-T Cell Function through a Targeted Cytokine Delivery System Utilizing CAR Target-Modified Extracellular Vesicles

Prediction of Organs Toxicity during CAR T-Cell Therapy By Using Cell-Free DNA Markers

3D Live Imaging and Phenotyping of the Subcellular Cytotoxicity in CAR-T Cell Immunotherapy

Reflecting In Vivo Spatio-Temporal Distribution Characteristics of CAR-T Cells through Real-World Clinical Samples

Functional Diversification and Dynamics of CAR-T Cells in B-ALL Patients

Soluble PD-L1 Predicts Poor Outcome and Disease Progression in Patients with De Novo Myelodysplastic Syndromes

MIP3α As an Early Prognostic Predictor for Patients with B-Cell Malignancies Receiving CD19/CD22-Redirected CAR T-Cell Cocktail Therapy

Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

A Phase 1/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

A phase 1 study of a novel fully human BCMA-targeting CAR (CT103A) in patients with relapsed/refractory multiple myeloma

CD19/CD22 CAR-T Cell Cocktail Therapy Following Autologous Transplantation in Patients with Relapsed/Refractory B-Cell Lymphomas

Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies

Efficacy and Safety of Fully Human Bcma Targeting CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma

Autonomous Ca 2+ Oscillations Reflect Oncogenic Signaling in B-ALL Cells

Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only